

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-32. (cancelled)

33. (previously presented) A system for managing batches of immunocompetent cells collected from human or animal subjects for their deferred use, said system comprising for each of said human or animal subjects:

- a storage device for conditioning and preserving batches of immunocompetent cells successively collected, into one or more storage centers,

- a personal library processor for constituting from said collected batches a personal library of immunocompetent cells, said personal library cumulating a sum of immunity information stored in the membranes of collected immunocompetent cells,

- a collection device for collecting, during successive collections of batches, information that is characteristic of said human or animal subject's status of health and/or psychological status, before or during immunocompetent cells collection, said status characterizing information being obtained by processing measurements made on samples of blood and/or fluid

and secretions and/or hair collected on said human or animal subject,

- a status-characterizing information device processing said status-characterizing information to determine said subject's identity data, said identity data including immunity-related data, historical and clinical data on previous diseases, treatments and therapeutic protocols experienced by said subject, said status-characterizing information device comprising an expert system wherein said status-characterizing information corresponding to said subject are entered in the form of biological items to which a set of rules stored in a knowledge base is applied, implementing into said expert system a process for determining a deferred-use protocol, said deferred-use protocol comprising biological and technical indications required for cell processing before re-use of a batch of immunocompetent cells previously collected from said subject,

- a cell management database processor for storing said subject's identity data successively determined into a cell management database,

- an identification device for performing identification of the personal batches of cells and a consulting device for consulting said cell management database, and

- a processor for processing said successively collected subject's identity data to determine parameters of a deferred-use protocol for said identified batches of

immunocompetent cells, said processor configured for upon prescription of a re-use process of immunocompetent cells for said subject:

- determining parameters of said deferred-use protocol, using data stored in said database, said determined parameters including optimized proportions of various selected types of cells among cells stored in said personal cell library for better tolerance by said patient and a greater reaction speed, using the subject's immunity data stored in said database, and

- determining said selected immunocompetent cells for extraction from said personal cell library.

34. (currently amended) The ~~device~~ system according to claim 33, further comprising a bio-electronic device for collecting bio-electronic information.

35. (cancelled)

36. (previously presented) A method for managing batches of immunocompetent cells collected from human or animal subjects for deferred use, comprising for each of said human subjects:

- plural successive cell collections stages of collecting immunocompetent cells collected from a human or animal subject for deferred use;

storing the collected cells, in a storage device for conditioning and preserving the collected cells, into one or more storage centers;

constituting for said subject, a personal cell library from the successively collected cells and a personal database, stored within a physical medium accessible by a computer system, containing:

data resulting from successive status characterization stages effected before or during each cell collection stage, said data comprising information on said subject's physiologic identity and state of health, and

subject's identity data generated by use of an expert system executed within the computer system and wherein said status-characterizing information corresponding to said subject are entered in the form of biological items to which a set of rules stored in a knowledge base is applied,

implementing into said expert system a process for determining a deferred-use protocol, said deferred-use protocol comprising biological and technical indications required for cell processing before re-use of a batch of immunocompetent cells previously collected from said subject,

upon prescription of a re-use process of immunocompetent cells for said subject:

- determining parameters of said deferred-use protocol, using data stored in said database, said

determined parameters including optimal proportions of various selected types of cells among cells stored in said personal cell library for better tolerance by said patient and a greater reaction speed, using subject's immunity data stored in said database,

- extracting said selected immunocompetent cells from said personal cell library, and

- processing said extracted immunocompetent cells according to said deferred-use protocol, in view or re-using said processed cells into said subject.

37. (previously presented) The method according to claim 36, comprising the further step of:

plural successive status-characterization stages of collecting information characteristic of the status of health and/or the psychological status of said subject, said status-characterizing information being obtained by processing measurements made on samples selected from a group consisting of blood, fluid, secretions, hair and combinations thereof from said subject, said status-characterizing information yielding a subject status characterization result indicating the status of health status and/or the psychological status of said subject, and said collecting step further including

i) conditioning and preserving said collected cells in batches of immunocompetent cells, said batches being stored into one or more storage centers, and

ii) constituting from said collected cells, a personal cell library of immunocompetent cells, said personal cell library containing a sum of immunity information stored in the membranes of the collected immunocompetent cells from one or more of said batches of immunocompetent cells.

38. (previously presented) The method according to claim 37, further comprising implementing said method in a gene therapy protocol.

39. (previously presented) The method according to claim 37, further comprising cryo-preserving a batch of immunocompetent cells.

40. (previously presented) The method according to claim 37, wherein the status-characterizing information comprise bioelectronic information resulting from processing respective measures of pH, oxidation-reduction potential Rh2 and resistivity ρ of blood previously collected on said human or animal subject,

41. (currently amended) The method according to claim 37, further comprising ~~before any re-use of a batch of~~

~~immunocompetent cells previously collected,~~ a step for checking the annihilation of the annihilating antibodies in the batches of immunocompetent cells before any re-use of a batch within said batch.

42. (previously presented) The method according to claim 37, further comprising during conditioning a batch of immunocompetent cells previously collected, a step for immunomagnetically selecting purified lymphocytes or monocytes.

43. (previously presented) The method according to claim 37, wherein said database is located within a management center controlling said one or more storage centers.

44. (currently amended) The method according to claim 36 ~~prepare~~ further comprising preparing an autologous vaccine using specific parameters of T4/T8 ratio.

45. (previously presented) The method according to claim 44, wherein the autologous vaccine is a vaccine for flu with cytotoxic activity.

46. (previously presented) The method according to claim 44, wherein the autologous vaccine is a vaccine to be injected in the lymphatic system of a subject.

47. (currently amended) The method according to claim 46, comprising a further step for checking [[the]] antibodies in the batches of immunocompetent cells prior to be annihilated in order not to harm the receiver prior to the injection and annihilating those that would harm the receiver in the lymphatic system.

48. (currently amended) The method according to claim 37 prepare further comprising preparing an autologous vaccine using specific parameters of T4/T8 ratio.

49. (currently amended) The method according to claim 38 prepare further comprising preparing an autologous vaccine using specific parameters of T4/T8 ratio.

50. (currently amended) The method according to claim 39 prepare further comprising preparing an autologous vaccine using specific parameters of T4/T8 ratio.

51. (currently amended) The method according to claim 40 prepare further comprising preparing an autologous vaccine using specific parameters of T4/T8 ratio.

52. (currently amended) The method according to claim
41 ~~prepare~~ further comprising preparing an autologous vaccine
using specific parameters of T4/T8 ratio.

53. (currently amended) The method according to claim
42 ~~prepare~~ further comprising preparing an autologous vaccine
using specific parameters of T4/T8 ratio.

54. (currently amended) The method according to claim
43 ~~prepare~~ further comprising preparing an autologous vaccine
using specific parameters of T4/T8 ratio.